Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles

Liron D Grossmann; John M Maris

doi:10.1002/1878-0261.12880

Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles

Mol Oncol. 2021 Feb;15(2):347-349. doi: 10.1002/1878-0261.12880. Epub 2020 Dec 26.

Authors

Liron D Grossmann¹, John M Maris¹

Affiliation

¹ Department of Pediatrics and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Abstract

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.

Keywords: 11q deletion; anti-GD2 therapy; immune checkpoint inhibition; microRNAs.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Genomics
Humans
Immunosuppression Therapy
Immunotherapy
Neuroblastoma* / genetics

Grants and funding

R35 CA220500/CA/NCI NIH HHS/United States